Developer docs
API playgroundTry for free, no card

Search company profiles

Quell Therapeutics

Full company profile

uuid00007z2

Namestring
Quell Therapeutics
Legal namestring
Quell Therapeutics Limited
Websiteurl
quell-tx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Quell Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in London (Translation & Innovation Hub, 84 Wood Lane) with a secondary presence in Boston, employing 101–250 people. It develops engineered T-regulatory (Treg) cell therapies using its proprietary Phenotype Locked™ CAR-Treg platform, which combines CAR constructs with a Foxp3 phenotype lock and synthetic cytokine receptors to produce stable, targeted Treg cells that durably engraft and suppress aberrant immune responses. The wholly-owned pipeline includes QEL-001 (HLA-A2 CAR-Treg for liver transplantation, Phase 1/2 LIBERATE, currently paused), QEL-005 (CD19 CAR-Treg for refractory rheumatoid arthritis and systemic sclerosis, Phase 1/2 CHILL across UK, Germany, and Spain), QEL-004 (Pan-Liver CAR for liver autoimmune disease, discovery), and QEL-ALLO (off-the-shelf allogeneic Treg programs, discovery). AstraZeneca holds rights to QEL-002 (islet-targeted CAR-Treg for type 1 diabetes) and QEL-003 (CAR-Treg for inflammatory bowel disease) under a $2.1 billion collaboration announced in September 2025.

Quell's business model is dual-track. Short term, it operates as an R&D-focused biotech: it generates no commercial product revenue, funds operations primarily through equity capital ($156M Series B in November 2021, prior Series B of $84M in 2021 and seed of $44.5M in 2019) and shareholder support, with Syncona as the largest backer at a 33.7% stake. Long term, the company is structured to monetize through (i) pharma partnerships with milestone and royalty streams — exemplified by the AstraZeneca deal — and (ii) potential direct commercialization of wholly-owned Treg products. Go-to-market for wholly-owned candidates runs through specialist transplant centers and rheumatology hospital sites via multinational Phase 1/2 trials, with future commercialization expected via partnership or co-promotion given the cell therapy manufacturing, logistics, and reimbursement complexity.

The customer base is clinical rather than commercial: end-users are patients with severe immune-mediated disease (liver transplant recipients, refractory RA and systemic sclerosis patients, and — under partnership — T1D and IBD patients), while enterprise counterparties are specialist hospital sites, academic collaborators (KCL, UCL, University Health Network, Hannover Medical School, University of Florida, University of Pittsburgh), and large-pharma partners (AstraZeneca). Pricing for approved products is not yet disclosed and will be set at/after regulatory approval.

Short descriptiontext

Quell Therapeutics is a clinical-stage biotech engineering T-regulatory cell therapies on its proprietary Phenotype Locked™ CAR-Treg platform to treat severe immune-mediated diseases, including organ transplant rejection and refractory autoimmune conditions, and serves specialist hospital sites and pharma partners such as AstraZeneca.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
engineered cell therapy, Treg cell therapies, CAR-Treg platform, transplant tolerance therapy, autoimmune cell therapy
Industry3 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Engineered Cell Therapy / Treg Cell Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Treg Cell Therapy Commercialization
TypeOne Time License
Description

As a clinical-stage biotech, Quell has no current revenue. The company is developing engineered CAR-Treg therapies across transplantation, neuroinflammatory, and autoimmune disease indications. Anticipated revenue will derive from product sales of approved therapies and/or licensing/royalty streams from pharma partnerships. The AstraZeneca collaboration ($2.1B deal) includes potential milestone and royalty payments.

prnewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Quell Therapeutics is a clinical-stage biotechnology company developing engineered T-regulatory (Treg) cell therapies designed to induce antigen-specific immune tolerance. Its product engine, the proprietary Phenotype Locked™ platform, supports multiple modalities including CAR-Treg, TCR-Treg, and allogeneic HLA-matched Treg cell therapies aimed at organ transplant tolerance and autoimmune diseases. Lead candidates target liver transplantation rejection, inflammatory bowel disease, type 1 diabetes, and broader autoimmune indications, with selected assets partnered with AstraZeneca.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CAR-Tregs remained detectable in circulation for over one year with durable engraftment in liver tissue
+3 more records
Product overview1 text field

Quell Therapeutics is a clinical-stage biotechnology company developing engineered T-regulatory (Treg) cell therapies built on its proprietary Phenotype Locked™ CAR-Treg platform. The company's portfolio includes wholly-owned programs (QEL-001, QEL-004, QEL-005, QEL-ALLO) and partnered programs with AstraZeneca (QEL-002, QEL-003). QEL-001 is an HLA-A2 targeted CAR-Treg for liver transplantation in Phase 1/2; QEL-005 is a CD19-directed CAR-Treg for rheumatologic autoimmune diseases in Phase 1/2. QEL-ALLO represents off-the-shelf allogeneic Treg candidates. The platform utilizes phenotype-locking, synthetic cytokine receptors, and multi-modular engineering to enhance Treg stability and therapeutic potential.

Product and service6 records
1QEL-001
CategoryEngineered Treg cell therapy
Description

Engineered autologous Treg cell therapy candidate aimed at inducing immune tolerance in liver transplant recipients to prevent graft rejection, being clinically advanced by Quell in transplant indications.

2QEL-002
CategoryEngineered Treg cell therapy
Description

Engineered Treg cell therapy candidate targeting type 1 diabetes, co-developed and partnered with AstraZeneca for antigen-specific immune tolerance induction in autoimmune disease.

3QEL-003
CategoryEngineered Treg cell therapy
Description

Engineered Treg cell therapy candidate targeting inflammatory bowel disease (IBD), co-developed and partnered with AstraZeneca for antigen-specific immune tolerance in autoimmune disease of the gut.

4QEL-004
CategoryEngineered Treg cell therapy
Description

Engineered Treg cell therapy candidate directed at autoimmune indications affecting the liver, developed by Quell using its Phenotype Locked™ platform for antigen-specific tolerance.

5QEL-005
CategoryEngineered Treg cell therapy
Description

Engineered Treg cell therapy candidate being developed by Quell for autoimmune disease indications, extending the Phenotype Locked™ platform beyond transplantation and into broader autoimmune therapy.

6QEL-ALLO
CategoryEngineered Treg cell therapy
Description

Allogeneic, HLA-matched engineered Treg cell therapy program intended to support off-the-shelf, scalable Treg cell products across Quell's autoimmune and transplant tolerance pipeline.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-23
Description

AstraZeneca partnership valued at $2.1 billion (comprising upfront, development, and commercial milestones plus royalties) for the co-development and commercialization of QEL-002 (islet-targeted CAR-Treg for type 1 diabetes) and QEL-003 (CAR-Treg for inflammatory bowel disease). AstraZeneca brings global pharmaceutical commercialization infrastructure. The partnership exemplifies immunology following hemato-oncology's path of targeted and potentially curative therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Academic partner of Quell Therapeutics for Treg biology research and translational product development. Quell collaborates with leading academic institutions to unlock biologic insights and optimize its highly translational product development cycle.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Academic partner collaborating with Quell on Treg biology and translational research. Quell works with leading academic institutions to unlock biologic insights and optimize product development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Academic partner (based in Canada) collaborating with Quell on Treg biology research and cell therapy development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Academic partner collaborating with Quell on Treg biology research, listed among Quell's academic collaborators.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Academic partner collaborating with Quell on Treg biology research, listed among Quell's academic collaborators.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Academic partner collaborating with Quell on Treg biology research, listed among Quell's academic collaborators.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Clinical-stage genomic medicine company developing cell and gene therapies including engineered Tregs and zinc finger nuclease-based platforms. Comparable to Quell for shared cell engineering capabilities and Treg therapy interests.

TypeBroad incumbent
Description

Clinical-stage gene-editing company developing CRISPR/Cas9-based cell therapies including CAR-T candidates. Comparable to Quell for shared cell engineering platform technology and gene-editing enabling capabilities for next-generation cell therapies.

TypeDirect peer
Description

Clinical-stage biotech developing allogeneic CAR-T cell therapies for cancer and autoimmune disease. Comparable to Quell for shared allogeneic cell therapy platform ambitions (QEL-ALLO) and CAR-T engineering expertise.

TypeBroad incumbent
Description

Clinical-stage gene-editing company developing CRISPR-based cell therapies including engineered T-cell candidates. Comparable to Quell for shared gene editing and cell therapy infrastructure enabling next-generation Treg and CAR-T products.

TypeDirect peer
Description

Clinical-stage CAR-T cell therapy company focused on autoimmune diseases, including rheumatologic indications like RA. Directly comparable to Quell's QEL-005 given overlapping CAR-T-for-autoimmune strategy and target patient populations.

TypeDirect peer
Description

Clinical-stage biotech developing CAR-T cell therapies designed to reset immune tolerance in autoimmune disease. Comparable to Quell for its cell therapy approach to B-cell-mediated autoimmune conditions and overlap with QEL-005's indications.

TypeBroad incumbent
Description

Clinical-stage cell therapy company developing engineered T-cell receptor (TCR) therapies. Comparable to Quell for shared expertise in engineering T-cells with synthetic receptors (CAR vs TCR) and cell therapy manufacturing capabilities.

TypeDirect peer
Description

Clinical-stage biotech developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Most direct comparable to Quell given shared Treg cell therapy focus and similar autoimmune indications.

9Abata Therapeutics
TypeDirect peer
Description

Clinical-stage company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, including multiple sclerosis and type 1 diabetes. Highly comparable to Quell's Treg platform and overlapping T1D indication (QEL-002).

TypeDirect peer
Description

Clinical-stage cell therapy company developing allogeneic T-cell and Treg-based therapies for autoimmune disease and oncology. Comparable to Quell for shared focus on engineered T-cell therapies for immune-mediated disease and allogeneic approach overlapping with QEL-ALLO.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quell Therapeutics

Engineered Cell Therapy / Treg Cell Therapeuticsquell-tx.com

Quell Therapeutics is a clinical-stage biotech engineering T-regulatory cell therapies on its proprietary Phenotype Locked™ CAR-Treg platform to treat severe immune-mediated diseases, including organ transplant rejection and refractory autoimmune conditions, and serves specialist hospital sites and pharma partners such as AstraZeneca.

What Quell Therapeutics does

Quell Therapeutics is a clinical-stage biotechnology company founded in 2019 and headquartered in London (Translation & Innovation Hub, 84 Wood Lane) with a secondary presence in Boston, employing 101–250 people. It develops engineered T-regulatory (Treg) cell therapies using its proprietary Phenotype Locked™ CAR-Treg platform, which combines CAR constructs with a Foxp3 phenotype lock and synthetic cytokine receptors to produce stable, targeted Treg cells that durably engraft and suppress aberrant immune responses. The wholly-owned pipeline includes QEL-001 (HLA-A2 CAR-Treg for liver transplantation, Phase 1/2 LIBERATE, currently paused), QEL-005 (CD19 CAR-Treg for refractory rheumatoid arthritis and systemic sclerosis, Phase 1/2 CHILL across UK, Germany, and Spain), QEL-004 (Pan-Liver CAR for liver autoimmune disease, discovery), and QEL-ALLO (off-the-shelf allogeneic Treg programs, discovery). AstraZeneca holds rights to QEL-002 (islet-targeted CAR-Treg for type 1 diabetes) and QEL-003 (CAR-Treg for inflammatory bowel disease) under a $2.1 billion collaboration announced in September 2025.

Quell's business model is dual-track. Short term, it operates as an R&D-focused biotech: it generates no commercial product revenue, funds operations primarily through equity capital ($156M Series B in November 2021, prior Series B of $84M in 2021 and seed of $44.5M in 2019) and shareholder support, with Syncona as the largest backer at a 33.7% stake. Long term, the company is structured to monetize through (i) pharma partnerships with milestone and royalty streams — exemplified by the AstraZeneca deal — and (ii) potential direct commercialization of wholly-owned Treg products. Go-to-market for wholly-owned candidates runs through specialist transplant centers and rheumatology hospital sites via multinational Phase 1/2 trials, with future commercialization expected via partnership or co-promotion given the cell therapy manufacturing, logistics, and reimbursement complexity.

The customer base is clinical rather than commercial: end-users are patients with severe immune-mediated disease (liver transplant recipients, refractory RA and systemic sclerosis patients, and — under partnership — T1D and IBD patients), while enterprise counterparties are specialist hospital sites, academic collaborators (KCL, UCL, University Health Network, Hannover Medical School, University of Florida, University of Pittsburgh), and large-pharma partners (AstraZeneca). Pricing for approved products is not yet disclosed and will be set at/after regulatory approval.

Quell Therapeutics firmographics

Firmographics
Name
Quell Therapeutics
Legal name
Quell Therapeutics Limited
Website
https://quell-tx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Quell Therapeutics is a clinical-stage biotech engineering T-regulatory cell therapies on its proprietary Phenotype Locked™ CAR-Treg platform to treat severe immune-mediated diseases, including organ transplant rejection and refractory autoimmune conditions, and serves specialist hospital sites and pharma partners such as AstraZeneca.
Ownership category
akta.pro rank

Quell Therapeutics industry classification

Industry
Product category
Engineered Cell Therapy / Treg Cell Therapeutics
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Engineered cell therapy
  • Treg cell therapies
  • CAR-Treg platform
  • Transplant tolerance therapy
  • Autoimmune cell therapy

Where Quell Therapeutics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Quell Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

  1. Treg Cell Therapy Commercialization: As a clinical-stage biotech, Quell has no current revenue. The company is developing engineered CAR-Treg therapies across transplantation, neuroinflammatory, and autoimmune disease indications. Anticipated revenue will derive from product sales of approved therapies and/or licensing/royalty streams from pharma partnerships. The AstraZeneca collaboration ($2.1B deal) includes potential milestone and royalty payments.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Quell Therapeutics product offering

Product offering

Core offering

Quell Therapeutics is a clinical-stage biotechnology company developing engineered T-regulatory (Treg) cell therapies designed to induce antigen-specific immune tolerance. Its product engine, the proprietary Phenotype Locked™ platform, supports multiple modalities including CAR-Treg, TCR-Treg, and allogeneic HLA-matched Treg cell therapies aimed at organ transplant tolerance and autoimmune diseases. Lead candidates target liver transplantation rejection, inflammatory bowel disease, type 1 diabetes, and broader autoimmune indications, with selected assets partnered with AstraZeneca.

Product overview

Quell Therapeutics is a clinical-stage biotechnology company developing engineered T-regulatory (Treg) cell therapies built on its proprietary Phenotype Locked™ CAR-Treg platform. The company's portfolio includes wholly-owned programs (QEL-001, QEL-004, QEL-005, QEL-ALLO) and partnered programs with AstraZeneca (QEL-002, QEL-003). QEL-001 is an HLA-A2 targeted CAR-Treg for liver transplantation in Phase 1/2; QEL-005 is a CD19-directed CAR-Treg for rheumatologic autoimmune diseases in Phase 1/2. QEL-ALLO represents off-the-shelf allogeneic Treg candidates. The platform utilizes phenotype-locking, synthetic cytokine receptors, and multi-modular engineering to enhance Treg stability and therapeutic potential.

Differentiator

Problem solved

Functional benefit

Products and services

  • QEL-001 Engineered autologous Treg cell therapy candidate aimed at inducing immune tolerance in liver transplant recipients to prevent graft rejection, being clinically advanced by Quell in transplant indications.
  • QEL-002 Engineered Treg cell therapy candidate targeting type 1 diabetes, co-developed and partnered with AstraZeneca for antigen-specific immune tolerance induction in autoimmune disease.
  • QEL-003 Engineered Treg cell therapy candidate targeting inflammatory bowel disease (IBD), co-developed and partnered with AstraZeneca for antigen-specific immune tolerance in autoimmune disease of the gut.
  • QEL-004 Engineered Treg cell therapy candidate directed at autoimmune indications affecting the liver, developed by Quell using its Phenotype Locked™ platform for antigen-specific tolerance.
  • QEL-005 Engineered Treg cell therapy candidate being developed by Quell for autoimmune disease indications, extending the Phenotype Locked™ platform beyond transplantation and into broader autoimmune therapy.
  • QEL-ALLO Allogeneic, HLA-matched engineered Treg cell therapy program intended to support off-the-shelf, scalable Treg cell products across Quell's autoimmune and transplant tolerance pipeline.

Quantifiable outcome

  • CAR-Tregs remained detectable in circulation for over one year with durable engraftment in liver tissue
  • +3 more outcomes

Companies that use Quell Therapeutics

Customer profile

Segments5 records

Ideal customer profiles2 records

Quell Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Quell Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship and core.

  • AstraZenecaflagshipStrategic or Co-development Partner · 23 September 2025AstraZeneca partnership valued at $2.1 billion (comprising upfront, development, and commercial milestones plus royalties) for the co-development and commercialization of QEL-002 (islet-targeted CAR-Treg for type 1 diabetes) and QEL-003 (CAR-Treg for inflammatory bowel disease). AstraZeneca brings global pharmaceutical commercialization infrastructure. The partnership exemplifies immunology following hemato-oncology's path of targeted and potentially curative therapies.
  • Kings College LondoncoreStrategic or Co-development Partner · 1 January 2021Academic partner of Quell Therapeutics for Treg biology research and translational product development. Quell collaborates with leading academic institutions to unlock biologic insights and optimize its highly translational product development cycle.
  • University College LondoncoreStrategic or Co-development Partner · 1 January 2021Academic partner collaborating with Quell on Treg biology and translational research. Quell works with leading academic institutions to unlock biologic insights and optimize product development.
  • University Health NetworkcoreStrategic or Co-development Partner · 1 January 2021Academic partner (based in Canada) collaborating with Quell on Treg biology research and cell therapy development.
  • Hannover Medical SchoolcoreStrategic or Co-development Partner · 1 January 2021Academic partner collaborating with Quell on Treg biology research, listed among Quell's academic collaborators.
  • University of FloridacoreStrategic or Co-development Partner · 1 January 2021Academic partner collaborating with Quell on Treg biology research, listed among Quell's academic collaborators.
  • University of PittsburghcoreStrategic or Co-development Partner · 1 January 2021Academic partner collaborating with Quell on Treg biology research, listed among Quell's academic collaborators.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Quell Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Sangamo Therapeutics: Clinical-stage genomic medicine company developing cell and gene therapies including engineered Tregs and zinc finger nuclease-based platforms. Comparable to Quell for shared cell engineering capabilities and Treg therapy interests.
  • Crispr Therapeutics: Clinical-stage gene-editing company developing CRISPR/Cas9-based cell therapies including CAR-T candidates. Comparable to Quell for shared cell engineering platform technology and gene-editing enabling capabilities for next-generation cell therapies.
  • Editas Medicine: Clinical-stage gene-editing company developing CRISPR-based cell therapies including engineered T-cell candidates. Comparable to Quell for shared gene editing and cell therapy infrastructure enabling next-generation Treg and CAR-T products.
  • Adaptimmune: Clinical-stage cell therapy company developing engineered T-cell receptor (TCR) therapies. Comparable to Quell for shared expertise in engineering T-cells with synthetic receptors (CAR vs TCR) and cell therapy manufacturing capabilities.

Direct peers

  • Allogene Therapeutics: Clinical-stage biotech developing allogeneic CAR-T cell therapies for cancer and autoimmune disease. Comparable to Quell for shared allogeneic cell therapy platform ambitions (QEL-ALLO) and CAR-T engineering expertise.
  • Kyverna Therapeutics: Clinical-stage CAR-T cell therapy company focused on autoimmune diseases, including rheumatologic indications like RA. Directly comparable to Quell's QEL-005 given overlapping CAR-T-for-autoimmune strategy and target patient populations.
  • Cabaletta Bio: Clinical-stage biotech developing CAR-T cell therapies designed to reset immune tolerance in autoimmune disease. Comparable to Quell for its cell therapy approach to B-cell-mediated autoimmune conditions and overlap with QEL-005's indications.
  • Sonoma Biotherapeutics: Clinical-stage biotech developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases. Most direct comparable to Quell given shared Treg cell therapy focus and similar autoimmune indications.
  • Abata Therapeutics: Clinical-stage company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, including multiple sclerosis and type 1 diabetes. Highly comparable to Quell's Treg platform and overlapping T1D indication (QEL-002).
  • Atara Biotherapeutics: Clinical-stage cell therapy company developing allogeneic T-cell and Treg-based therapies for autoimmune disease and oncology. Comparable to Quell for shared focus on engineered T-cell therapies for immune-mediated disease and allogeneic approach overlapping with QEL-ALLO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Quell Therapeutics social profiles

Digital presence

Quell Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quell Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Quell Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quell Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quell Therapeutics

What does Quell Therapeutics do?

Quell Therapeutics is a clinical-stage biotechnology company developing engineered T-regulatory (Treg) cell therapies designed to induce antigen-specific immune tolerance. Its product engine, the proprietary Phenotype Locked™ platform, supports multiple modalities including CAR-Treg, TCR-Treg, and allogeneic HLA-matched Treg cell therapies aimed at organ transplant tolerance and autoimmune diseases. Lead candidates target liver transplantation rejection, inflammatory bowel disease, type 1 diabetes, and broader autoimmune indications, with selected assets partnered with AstraZeneca.

Is Quell Therapeutics a public or private company?

Quell Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Quell Therapeutics founded?

Quell Therapeutics was founded in 2019. It employs 101 to 250 people.

Where is Quell Therapeutics based?

Quell Therapeutics is headquartered in London, United Kingdom, in the Europe region.

How does Quell Therapeutics make money?

One revenue line is on record: treg Cell Therapy Commercialization.

Who are Quell Therapeutics's main competitors?

Broad incumbents on record are Sangamo Therapeutics, Crispr Therapeutics, Editas Medicine and Adaptimmune. Direct peers are Allogene Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Sonoma Biotherapeutics, Abata Therapeutics and Atara Biotherapeutics.

Does Quell Therapeutics have an API?

No public API is recorded for Quell Therapeutics.

What industry is Quell Therapeutics in?

Quell Therapeutics's product category is Engineered Cell Therapy / Treg Cell Therapeutics. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswirePromising Early Safety Data as Quell Therapeutics Advances QEL-005 – a Novel Engineered nTreg Therapy – to Second Dose Cohort in CHILL Phase 1/2 Trial in Difficult-to-Treat Rheumatoid Arthritis and Systemic SclerosisQuell Therapeutics announced QEL-005 advanced to the second dose cohort in the CHILL Phase 1/2 trial for rheumatoid arthritis and systemic sclerosis. The first cohort was well tolerated with no dose-limiting toxicities, serious adverse events, or infusion reactions. Initial clinical data are expected in H1 2027.Labiotech.euEight CAR-T companies tackling autoimmune disordersEight biotech companies are developing CAR-T therapies for autoimmune diseases, with Kyverna's miv-cel in phase 3 for stiff person syndrome and Cabaletta's rese-cel in phase 1/2 for lupus and myositis. Other candidates include Descartes-08, obe-cel, and ALLO-329, with some in phase 3 trials. No CAR-T treatments are yet approved for autoimmune conditions.Investing.comEarnings call transcript: Syncona H2 2026 NAV flat as biotech catalysts build By Investing.comSyncona Limited reported that net asset value per share was roughly flat for the full year ended March 2026, as gains from its Beacon Therapeutics stake were offset by write-downs at Kesmalea and the CRT Pioneer Fund. The London-listed life sciences investor holds GBP 198 million in available capital and has deployed 84% of its GBP 81 million annual investment into late-stage and clinical assets, with 86% of its portfolio now at clinical or commercial stage. Management flagged five key value inflection points expected in calendar 2026, including data readouts from Beacon, iOnctura, Resolution, and Quell, while targeting a minimum of GBP 250 million in shareholder returns through M&A exits.Investing.comEarnings call transcript: Syncona H2 2026 NAV flat as biotech catalysts build By Investing.comSyncona Limited, a London-listed life sciences investor, reported that NAV per share was roughly flat for the full year ended March 2026, as gains from its Beacon Therapeutics stake were offset by write-downs at Kesmalea and the CRT Pioneer Fund. The company has GBP 198 million in available capital and deployed GBP 81 million during the year, with 86% of its portfolio now at clinical or commercial stage. Management highlighted five key value inflection points expected in calendar 2026, including data readouts from Beacon, iOnctura, Resolution, and Quell, as the company targets a minimum of GBP 250 million in realizations for shareholders.Investing.comQuell Therapeutics begins trial of autoimmune cell therapy By Investing.comQuell Therapeutics has initiated a Phase I/II clinical trial for QEL-005, an engineered CAR-Treg cell therapy for rheumatoid arthritis and systemic sclerosis, following approval from the UK medicines regulator. The multinational CHILL trial will enroll patients in the UK, Germany, and Spain, with clinical data expected in 2027. The company also reported positive interim data from its LIBERATE trial of QEL-001 in liver transplantation, showing CAR-Treg cell safety and functional stability for over one year, and will explore partnership opportunities for that program while prioritizing capital toward QEL-005.GlobeNewswireQuell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA ApprovalQuell Therapeutics initiated the CHILL Phase 1/2 trial of its CAR-Treg therapy QEL-005 in rheumatoid arthritis and systemic sclerosis after UK MHRA CTA approval. The multinational study will recruit up to 16 patients across the UK, Germany, and Spain, with early results expected in Q1 2027.GlobeNewswireQuell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant StudyQuell Therapeutics shared interim data from its LIBERATE Phase 1/2 trial of QEL-001 CAR-Tregs in liver transplant patients, reporting no serious adverse events and successful weaning from calcineurin inhibitors. All five weaned patients achieved CNI-free immunosuppression, with three reducing everolimus to very low doses. Quell will now focus on the QEL-005 CHILL trial for autoimmune diseases.PharmaTimesQuell launches chill phase 1/2 trial for novel cartreg therapyQuell Therapeutics has launched the CHILL Phase 1/2 clinical trial for QEL-005, an autologous CAR-Treg therapy targeting rheumatoid arthritis and systemic sclerosis, following UK Medicines and Healthcare products Regulatory Agency approval of its clinical trial application. The multinational study will enroll up to 16 adults across the UK, Germany, and Spain, with early findings expected in early 2027. The therapy, built on Quell's proprietary phenotype-locked CAR-Treg platform, uses a Treg-optimised CD19-directed CAR to selectively activate within inflamed tissues and suppress pro-inflammatory immune cells, distinguishing it from conventional B-cell-depleting CAR-T therapies.BioSpaceQuell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR-Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA ApprovalQuell Therapeutics has initiated the CHILL Phase 1/2 basket clinical trial evaluating its autologous CAR-Treg therapy QEL-005 in patients with Rheumatoid Arthritis and Systemic Sclerosis, following UK MHRA Clinical Trial Application approval. The multinational study will recruit up to 16 adult participants across the UK, Germany and Spain, with early clinical findings expected in Q1 2027. QEL-005 leverages Quell's proprietary Phenotype Locked™ CAR-Treg platform to selectively suppress immune activity within inflamed tissues, representing a differentiated approach from conventional B-cell depletion therapies.